Patents by Inventor Stephen M. Boyle

Stephen M. Boyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method producing an immune response for reducing the risk of developing brucellosis
    Publication number: 20120202271
    Abstract: This invention relates to unique antigens in a brucellosis vaccine which Provide an immune response against bacteria which cause brucellosis in cattle and Other animals. The vaccine specifically uses Bp26 and LeuB expressed to create the immunity.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 9, 2012
    Inventors: Gerhardt G. Schurig, Stephen M. Boyle, Nammalwar Sriranganathan
  • Producing an immune response for reducing the risk of developing brucellosis
    Publication number: 20120202270
    Abstract: This invention relates to unique antigens in a brucellosis vaccine which Provide an immune response against bacteria which cause brucellosis in cattle and other animals.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 9, 2012
    Inventors: Gerhardt G. Schurig, Stephen M. Boyle, Nammalwar Sriranganathan
  • Producing an immune response for reducing the risk of developing brucellosis
    Publication number: 20100226942
    Abstract: This document relates to materials and methods for producing an immune response for reducing the risk of developing brucellosis. For example, this document provides vaccines for administration to animals as well as methods for producing an immune response against bacteria that cause brucellosis using vaccines provided herein. The vaccines provided herein can be effective for reducing the risk of developing brucellosis from multiple species of Brucella.
    Type: Application
    Filed: October 21, 2009
    Publication date: September 9, 2010
    Inventors: Gerhardt G. Schurig, Stephen M. Boyle, Nammalwar Sriranganathan
  • Development of a live, attenuated, recombinant vaccine for Brucellosis
    Patent number: 7364745
    Abstract: A recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to the Brucella species is identified by detecting a genetic sequence for carboxyl-terminal (i.e. tail-specific) protease activity in a biological sample.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: April 29, 2008
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Aloka B. Bandara, Stephen M. Boyle, Nammalwar Sriranganathan, Gerhardt G. Schurig
  • Over-expressing homologous antigen vaccine and a method of making the same
    Patent number: 6811787
    Abstract: This invention relates to an over-expressing homologous antigen vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vaccine is an attenuated or avirulent pathogenic micro-organism that over-expresses at least one homologous antigen encoded by at least one gene derived from the pathogenic micro-organism, and may also express a heterologous antigen.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: November 2, 2004
    Assignees: The Regents of the University of California, Virginia Tech Intellectual Properties, Inc.
    Inventors: Stephen M. Boyle, Silvio Cravero, Lynette Corbeil, Gerhardt Schurig, Nammalwar Srirnaganathan, Ramesh Vemulapalli
  • Over-expressing homologous antigen vaccine and a method of making the same
    Publication number: 20030044431
    Abstract: This invention relates to an over-expressing homologous antigen vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vaccine is an attenuated or avirulent pathogenic micro-organism that over-expresses at least one homologous antigen encoded by at least one gene derived from the pathogenic micro-organism, and may also express a heterologous antigen.
    Type: Application
    Filed: October 11, 2002
    Publication date: March 6, 2003
    Inventors: Gerhardt Schurig, Stephen M. Boyle, Nammalwar Sriranganathan
  • Live vaccine against Brucellosis
    Patent number: 6444445
    Abstract: Live Brucella vaccines and methods for preparing the live vaccines protective against brucellosis are described. The vaccines are prepared by introducing a deletion in the rfbU gene of a strain of Brucella which results in attenuation of the strain while retaining the desired immunogenicity to initiate a protective immunogenic response. Other strains with varying levels of attenuation are described.
    Type: Grant
    Filed: January 22, 1998
    Date of Patent: September 3, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mikeljon P. Nikolich, David L. Hoover, Richard L. Warren, Luther E. Lindler, Ted L. Hadfield, Gerhardt G. Schurig, Stephen M. Boyle, John R. McOulston, Nammalwar Sriranganathan
  • LIVE VACCINE AGAINST BRUCELLOSIS
    Publication number: 20010014673
    Abstract: Live Brucella vaccines and methods for preparing the live vaccines protective against brucellosis are described. The vaccines are prepared by introducing a deletion in the rfbU gene of a strain of Brucella which results in attenuation of the strain while retaining the desired immunogenicity to initiate a protective immunogenic response. Other strains with varying levels of attenuation are described.
    Type: Application
    Filed: January 22, 1998
    Publication date: August 16, 2001
    Inventors: MIKELJON P. NIKOLICH, DAVID L. HOOVER, RICHARD L. WARREN, LUTHER E. LINDLER, TED L. HADFIELD, CERHARDT G. SCHURIG, STEPHEN M. BOYLE, JOHN R. MCOULSTON, NAMMALWAR SRIRANGANATHAN
  • Over-expressing homologous antigen vaccine and a method of making the same
    Patent number: 6149920
    Abstract: This invention relates to an over-expressing homologous antigen vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vaccine is an attenuated or avirulent pathogenic micro-organism that over-expresses at least one homologous antigen encoded by at least one gene derived from the pathogenic micro-organism, and may also express a heterologous antigen.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: November 21, 2000
    Assignees: The Regents of the University of California, Virginia Tech Intellectual Properties, Inc.
    Inventors: Stephen M. Boyle, Silvio Cravero, Lynette Corbeil, Gerhardt Schurig, Nammalwar Srirnaganathan, Ramesh Vemulapalli